CD22 and hairy cell leukemia: Meanwhile, clinical trials continued to evaluate the efficacy of the combination therapy in Ph(-) ALL and in pediatric patients.188,382,383 Another anti-CD22 ADC, called moxetumomab pasudotox, has been developed for the treatment of R/R hairy cell leukemia (HCL).189 In the long-term follow-up from the pivotal trial, complete responders lasting ≥60 months was 61% and median PFS without the loss of hematologic remission was 71.7 months.